![Douglas Swirsky](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Douglas Swirsky
Presidente presso
CELLECTAR BIOSCIENCES, INC.
Patrimonio netto: 100 593 $ in data 31/05/2026
Profilo
Douglas J.
Swirsky is currently Independent Chairman at Cellectar Biosciences, Inc. since 2017 and Chief Financial & Accounting Officer at Barinthus Biotherapeutics Plc starting in 2026.
Former roles include President, CEO, Secretary & Director at GenVec, Inc. from 2014 to 2017; President, CEO, CFO, Secretary & Director at Rexahn Pharmaceuticals, Inc. from 2018 to 2020; Chairman at Fibrocell Science, Inc. from 2016 to 2019; Chairman at MetaVia, Inc. from 2021 to 2022; Chairman at Castle Creek Biosciences, Inc.; Independent Director at PolyMedix, Inc. from 2011 to 2013; Managing Director at Stifel, Nicolaus & Co., Inc. from 2005 to 2006; Independent Non-Executive Director at Pernix Therapeutics Holdings, Inc. from 2017 to 2019; Chief Financial Officer, Treasurer & Director at AavantiBio, Inc. from 2020 to 2022; MD & Head-Life Sciences Investment Banking at Legg Mason, Inc. from 2002 to 2005; and Chief Financial & Accounting Officer at MaxCyte, Inc. from 2023 to 2026.
Education includes an undergraduate degree from Boston University in 1992 and an MBA from Kellogg School of Management in 1997.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
MAXCYTE, INC. 0,08% | 21/04/2026 | 82.919 ( 0,08% ) | 100 332 $ | 31/05/2026 |
| 19/05/2026 | 83 ( 0% ) | 261 $ | 31/05/2026 |
Posizioni attive di Douglas Swirsky
| Società | Posizione | Inizio |
|---|---|---|
| CELLECTAR BIOSCIENCES, INC. | Presidente | 01/08/2017 |
| BARINTHUS BIOTHERAPEUTICS PLC | Direttore Finanziario/CFO | 01/05/2026 |
Precedenti posizioni note di Douglas Swirsky
| Società | Posizione | Fine |
|---|---|---|
| MAXCYTE, INC. | Direttore Finanziario/CFO | 30/03/2026 |
Aavantibio, Inc.
 Aavantibio, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops new gene therapies | Presidente | 01/10/2020 |
| METAVIA INC. | Presidente | 14/01/2022 |
| REXAHN PHARMACEUTICALS, INC. | Amministratore Delegato | 01/11/2020 |
| FIBROCELL SCIENCE, INC. | Presidente | 13/12/2019 |
Formazione di Douglas Swirsky
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
76
Relazioni di 1° grado
15
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 15 |
|---|---|
Legg Mason, Inc.
 Legg Mason, Inc. Investment ManagersFinance Provides investment and asset management services | Finance |
Fibrocell Science, Inc.
 Fibrocell Science, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as an autologous cell and gene therapy company focused on development of personalized biologics to treat rare skin and connective tissue diseases | Commercial Services |
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology Develops bio-pharmaceutical products | Health Technology |
MaxCyte, Inc.
 MaxCyte, Inc. BiotechnologyHealth Technology Specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of therapeutic products | Health Technology |
PolyMedix, Inc.
 PolyMedix, Inc. Pharmaceuticals: MajorHealth Technology Develops synthetic small molecule compound drugs | Health Technology |
Stifel, Nicolaus & Co., Inc.
 Stifel, Nicolaus & Co., Inc. Investment Banks/BrokersFinance Provides brokerage services | Finance |
Boston University
 Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rexahn Pharmaceuticals, Inc.
 Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Pernix Therapeutics Holdings, Inc.
 Pernix Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products | Health Technology |
Kellogg School of Management
 Kellogg School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cellectar Biosciences, Inc.
 Cellectar Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that is engaged in developing compounds for the treatment and imaging of cancer | Health Technology |
NeuroBo Pharmaceuticals, Inc.
 NeuroBo Pharmaceuticals, Inc. BiotechnologyHealth Technology Researches and develops disease-modifying therapies for neurodegenerative diseases | Health Technology |
Castle Creek Biosciences, Inc.
 Castle Creek Biosciences, Inc. BiotechnologyHealth Technology Develops gene therapies for patients with skin and genetic diseases | Health Technology |
Aavantibio, Inc.
Aavantibio, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops new gene therapies | Health Technology |
Vaccitech Plc
 Vaccitech Plc Pharmaceuticals: MajorHealth Technology Discovers and develops immunotherapeutic products and vaccines for the treatment and prevention of infectious and cancer diseases | Health Technology |
